Pay in 4 interest-free payments of $7.28 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Clinical Study Results (TRIUMPH & TRANSCEND) Retatrutide is an investigational triple agonist targeting GLP-1, GIP, and glucagon receptors: Weight reduction: In phase 2 and phase 3 clinical studies, treated participants achieved approximately 24% to 28.7% weight loss over 4868 weeks
Hove emphasized that any potential risk must be weighed against the well-established benefits of GLP-1 medications, which include improved blood sugar control, significant weight loss and a reduced risk of cardiovascular disease
Encourage diet sources of B where possible, and adherence to the injection schedule.
What supplies should I bring beyond the medication
From there, board-certified providers write prescriptions, monitor safety, adjust doses as needed, and offer secure messaging support
